As part of the NUM research project NAPKON-TIP, the "RAPID_REVIVE" study is investigating treatment options for Post-COVID syndrome (PCS). The aim of the study is to investigate a possible positive influence of the as yet unapproved drug IMU-838 on the course of Post-COVID syndrome. Since the start of the study in August 2024, more than 100 patients at a total of 10 locations have already been included in the study. There is no approved therapy yet and patient interest is high. We expect at least 150 patients to be enrolled by the end of the official project period on 30 June 2025.
We would like to thank all participating partners, centres and study teams for their commitment so far!
Further information on the participating sites and the study can be found here.